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ABSTRACT
Introduction: Insulin analogues have become
increasingly popular despite their greater cost
compared with human insulin. The aim of this study
was to calculate the incremental cost to the National
Health Service (NHS) of prescribing analogue insulin
preparations instead of their human insulin
alternatives.
Methods: Open-source data from the four UK
prescription pricing agencies from 2000 to 2009 were
analysed. Cost was adjusted for inﬂation and reported
in UK pounds at 2010 prices.
Results: Over the 10-year period, the NHS spent
a total of £2732 million on insulin. The total annual
cost increased from £156 million to £359 million, an
increase of 130%. The annual cost of analogue insulin
increased from £18.2 million (12% of total insulin
cost) to £305 million (85% of total insulin cost),
whereas the cost of human insulin decreased from
£131 million (84% of total insulin cost) to £51 million
(14% of total insulin cost). If it is assumed that all
patients using insulin analogues could have received
human insulin instead, the overall incremental cost of
analogue insulin was £625 million.
Conclusion: Given the high marginal cost of analogue
insulin, adherence to prescribing guidelines
recommending the preferential use of human insulin
would have resulted in considerable ﬁnancial savings
over the period.
INTRODUCTION
The number of people diagnosed with dia-
betes in the UK has risen to 2.8 million,
1e4
with approximately 90% of these having type
2 diabetes.
5 Patients with type 1 diabetes
require insulin from diagnosis, whereas those
with type 2 diabetes tend to be switched to
insulin later in the natural history of their
disease.
6
Insulin analogues were developed to better
mimic the pharmacokinetic proﬁle of
endogenous insulin, thereby achieving more
optimal onset or duration of action and
simpler dosing regimens.
7 8 Since their
launch, the use of insulin analogues has
increased steadily.
9 In England, the annual
net ingredient cost (NIC) of analogue insulin
in 2004e2005 was £109.8 million (55% of
total insulin cost), which had risen to £255.2
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ARTICLE SUMMARY
Article focus
- Insulin analogues have become increasingly
popular in recent years.
- Insulin analogues are more costly than their
human insulin alternatives.
- The aim of this cross-sectional study is to
calculate the incremental cost to the National
Health Service (NHS) of prescribing analogue
insulin preparations instead of their human
insulin alternatives.
Key messages
- If all dispensations for analogue insulin between
2000 and 2009 had used a human insulin
alternative, the NHS would have saved an
estimated £625 million.
- Given the high marginal cost of analogue insulin,
adherence to prescribing guidelines recom-
mending the preferential use of human insulin
would have resulted in considerable ﬁnancial
savings over the period.
Strengths and limitations of this study
- The calculation of the incremental cost of
analogue insulin was based on an assumption
that the same volume of insulin would be
prescribed if patients were switched from
analogue to human insulin.
- Some data were missing from the Welsh
Prescription Cost Analysis (PCA) and had to be
estimated using PCAs from alternative countries
in alternative years. This cost was adjusted for
inﬂation and was unlikely to have impacted on
the estimates as a whole as the net ingredient
cost and volume of these products was small.
- PCA only includes information on how much
insulin was dispensed and not how many
prescriptions were collected by patients with
type 2 diabetes.
- There is no deﬁnitive ﬁgure on how many
patients with type 2 diabetes could have received
human insulin instead of analogue insulin.
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Open Access Researchmillion (85.3% of total insulin cost) by 2009e2010.
9
A similar trend was observed in the early 1980s when
human insulin was introduced and the use of animal
insulin decreased rapidly.
10 This occurred despite a lack
of evidence to indicate any beneﬁts of human over
animal insulin.
71 0The Institute for Quality and Efﬁ-
ciency in Healthcare (IQWiG) in Germany has ques-
tioned whether the beneﬁts of insulin analogues are
sufﬁcient to outweigh their increased cost.
11 12 In the
UK, the National Institute for Heath and Clinical
Excellence (NICE) recommends the use of human
neutral protamine Hagedorn insulin (NPH) as ﬁrst-line
therapy. Insulin glargine is only recommended in
speciﬁc circumstances, and not as ﬁrst-line therapy.
13
Accordingly, the aim of this study was to characterise
the pattern of insulin prescriptions dispensed between
2000 and 2009, inclusive, for the whole of the UK, and to
evaluate the marginal ﬁnancial cost to the National
Health Service (NHS) of using analogue insulin instead
of its equivalent human insulin preparation. This anal-
ysis formed the basis of the cost-saving estimates recently
presented by the BMJ and Channel 4 News.
14
METHODS
Open-source data from the four prescription pricing
agencies for England,
15 Northern Ireland,
16 Scotland
17
and Wales
18 were used in this study. The Prescription
Cost Analyses (PCAs) for England, Northern Ireland
and Wales describe the quantity and NIC of all NHS
prescriptions dispensed in primary care in the constit-
uent country. The NIC refers to the cost of the drug
before any discounts, and does not include any
dispensing costs or fees.
19 The PCA for Scotland spec-
iﬁes gross ingredient cost, which is equivalent to NIC in
the PCAs for England, Northern Ireland and Wales.
17
The PCAs for the four countries from 2000 to 2009 were
combined. Data were grouped into insulin types
according to their molecular origin (analogue, human-
sequence and animal-sequence) and also into indi-
vidual insulin types (insulin soluble, insulin isophane,
insulin zinc suspension mixed, insulin zinc suspension
crystalline, biphasic isophane insulin, protamine zinc
insulin, insulin aspart, insulin lispro, insulin detemir,
insulin glargine, biphasic insulin aspart, biphasic
insulin lispro and insulin glulisine). For the Welsh data
from 2000 to 2004, it was necessary to calculate the
quantity of each type of insulin dispensed from the NIC
per unit quantity from the PCAs for England, Scotland
or Northern Ireland, since the Welsh PCA data did not
include this information until 2005. If the drug name in
the PCA did not specify a presentation, that is a phial,
a pre-ﬁlled pen or a cartridge, then it was assumed to be
a phial.
All costs were adjusted for inﬂation, and they are
reported in UK pounds at 2010 prices using the gross
domestic product deﬂator published by HM Treasury.
20
The incremental cost of analogue insulin was calculated
by summing the NIC of analogue insulin and then
subtracting the cost of dispensing the same volume of
insulin of human origin.
The incremental cost of analogue insulin was also
calculated by assuming that if patients prescribed
analogue insulin had alternatively received human
insulin, they would still have received the same presen-
tation that is, a phial, a preﬁlled pen or a cartridge for
a reusable pen device, since patients and clinicians
favour the ease-of-administration offered by pen
devices.
21 22 Using data from a previous analysis of all
prescribing costs for diabetes throughout the UK,
23 we
were further able to estimate the relative volumes of
analogue and human insulin prescribed by the type of
diabetes.
RESULTS
Net ingredient cost of insulin in the UK, 2000e2009
Over the 10-year period, the NHS spent a total of £2732
million on insulin prescriptions. Prescriptions for
analogue insulin accounted for £1629 million (59%),
human insulin £1056 million (39%) and animal insulin
£47.2 million (2%).
The total annual cost of insulin rose from £156 million
in 2000 to £359 million in 2009, a 130% increase (ﬁgure
1). In 2000, the annual cost of analogue insulin was
£18.2 million, which represented only 12% of total
insulin cost, while the cost of human insulin was £131
million or 84% of the total insulin cost. Spending on
analogue insulin increased from £192 million (66% of
total insulin cost) in 2005, by which time all the currently
marketed insulin analogues had been launched, to £305
million (85% of total insulin cost) in 2009. During the
same period, the annual cost of human insulin fell from
£95.3 million (33%) to £51.1 million (14%). The cost of
animal insulin per year also decreased from £7.42
million (5%) in 2000 to just £3.07 million (1%) in 2009.
Incremental cost of analogue insulin in the UK, 2000e2009
The unit cost of each insulin preparation is listed in
table 1. Analogue insulin cost on average £2.31 per
millilitre and was therefore 47% more expensive than
human insulin at £1.57 per millilitre. In 2009, the mean
NIC per millilitre was £1.27 for human insulin and £2.25
for analogue insulin. The NIC per millilitre of human
and analogue insulin peaked in 2003 and 2004, respec-
tively. Compared with 2004 values, the NIC per millilitre
in 2009 had decreased by 27% for human insulin and by
7% for analogue insulin (table 2).
These unit costs were used to estimate the maximum,
annual, incremental cost of dispensing analogue insulin
assuming that all analogue prescriptions dispensed
could have been alternatively prescribed as human
insulin. Assuming 100% conversion, the annual incre-
mental cost of analogue insulin increased from £5.18
million in 2000 to £133 million in 2009 (table 3).
Overall, for the 10-year period, the total incremental cost
of analogue insulin was £625 million at 100% conversion
and £312 million at 50% conversion. Between 2005 and
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Incremental cost to the National Health Service of prescribing analogue insulin2009, the incremental cost of analogue insulin was £538
million at 100% conversion and £269 million at 50%
conversion.
Estimated cost by diabetes type
Patients with type 2 diabetes accounted for an estimated
£86.0 million of NHS expenditure on human and
analogue insulin in 2000, increasing to £229 million
(+166%) in 2009. For type 1 diabetes these values were
£62.7 million and £127 million, respectively (+103%).
Over the entire period, the total cost of insulin
prescribing for type 2 diabetes was £950 million for
insulin analogues and £708 million for human insulin
(see table 4). The incremental cost of analogue insulin
for patients with type 2 diabetes was estimated at £306
million at 100% conversion and £153 million at 50%
conversion.
Incremental cost of analogue insulin in the UK taking insulin
presentation into account, 2000e2009
Human insulin is more likely to be dispensed as a phial
when compared to insulin analogues which are typically
administered using a pen device (table 1). If all those
receiving analogue insulin had been dispensed human
insulin instead but the presentation had remained the
same (ie, a phial, a pen or a pen-ﬁll device), then the
incremental cost of analogue insulin in the UK between
2000 and 2009 would have been £271 million at 50%
conversion and £541 million at 100% conversion,
compared with £625 million at 100% conversion (table
3) if insulin presentation is not take into account.
DISCUSSION
Since their launch, insulin analogues have had an
increasing impact on the amount of resources used to
manage diabetes. The annual inﬂation-adjusted cost to
the NHS of insulin increased from £156 million in 2000
to £359 million in 2009 (a twofold increase). During the
same period, annual NHS spending on analogue insulin
increased from £18 million (12% of total insulin cost) to
£305 million (85% of total insulin cost), while annual
NHS spending on human insulin fell from £130 million
(84%) to £51.1 million (14%). If all dispensations for
analogue insulin between 2000 and 2009 had used the
equivalent human insulin, we estimate the NHS would
have saved £625 million.
While it has been shown that insulin analogues are
associated with reduced weight gain, less hypoglycaemia
(particularly nocturnal), improved lowering of post-
prandial glucose and improved dosing schedules, most
Table 1 Net ingredient cost (NIC) and volume of analogue and human insulin by presentation for the UK, 2000e2009
Insulin formulation NIC£2010 Volume (ml) Percentage NIC£2010/ml
Analogue insulin £1628566983 706275942 £2.31
Pen £705567792 285036913 40% £2.48
Penﬁll £839695265 362630874 51% £2.32
Phial £83303925 58608155 8% £1.42
Human insulin £1055956518 671922946 £1.57
Pen £218790437 117962069 18% £1.85
Penﬁll £645030389 373850061 56% £1.73
Phial £192135692 180110816 27% £1.07
Figure 1 The total annual cost of
insulin prescriptions for the UK,
2000e2009. NIC, net ingredient
cost.
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Incremental cost to the National Health Service of prescribing analogue insulincommentators agree that these beneﬁts are modest in
comparison to human insulin.
7 82 4However, the cost
effectiveness of analogue insulin is likely to vary
depending on the type of diabetes, the clinical charac-
teristics of the individual patient and the particular type
of analogue insulin. For example, rapid-acting insulin
analogues in patients with type 1 diabetes are likely to be
a cost-effective use of ﬁnite healthcare resources.
25 In
the NICE guidance for the management of patients with
type 2 diabetes, the use of human insulin is recom-
mended as ﬁrst-line therapy, and long-acting analogues
such as insulin glargine and premixed insulin are only
recommended in certain speciﬁc circumstances.
26 The
NICE has determined that insulin glargine borders on
being cost effective at current willingness to pay thresh-
olds in patients with type 1 diabetes but that it is not cost
effective in type 2 diabetes.
13 In Germany, the IQWiG
disputes the value of insulin analogues in type 2 dia-
betes.
11 12 In addition, the Pharmaceutical Management
Agency (PHARMAC) in New Zealand has approved
insulin glargine but only as second-line therapy and has
only recommended its use in those who are allergic to
conventional insulin or have failed to control their dia-
betes with conventional insulin.
27 A similar recommen-
dation has been made by the Canadian Agency for Drugs
and Technologies in Health where human insulin is
recommended as ﬁrst-line therapy and insulin analogues
are only recommended for patients who experience
signiﬁcant hypoglycaemia.
28 The longest trial comparing
insulin glargine with insulin isophane concluded that
there was a similar progression to retinopathy with the
two agents but less improvement in glycated haemo-
globin levels for the more expensive product, insulin
glargine (0.2%, p¼0.0053).
29 Furthermore, although the
period from 1997 to 2007 saw the introduction of insulin
analogues and a general increase in diabetes-related
care, this was not accompanied by an improvement in
glycated haemoglobin levels in patients with type 2 dia-
betes treated with insulin.
30 There is currently no
systematic means of measuring the other clinical beneﬁts
associated with analogue insulin, such as rate of symp-
tomatic or nocturnal hypoglycaemia, making it difﬁcult
to judge the real-world cost effectiveness of these drugs.
An analysis of open-source Hospital Episode Statistics
(HES) data shows that growth in hospital admissions for
hypoglycaemia has exceeded growth in the prescribing
of insulin.
31
The increase in the use of analogue insulin is likely to
be due in part to successful marketing. Some of the
manufacturers of insulin analogues also provided
professional support to general practitioners at the time
their analogue insulin was marketed, although this was
not conditional on the doctor prescribing their
insulin.
14 Insulin analogues were also available in new
devices that may be more appealing to patients and
easier to use than the devices used to administer human
insulin.
14 The fact that 40% of analogue insulin was
prescribed as a preﬁlled pen device compared with just
18% of human insulin supports this suggestion. Finally,
a move to patented insulin products has notable
commercial beneﬁts for manufacturers.
Since the introduction of insulin analogues, some
human insulin products have been withdrawn. Patients
using these products have switched to an alternative
product containing either human insulin or an insulin
analogue. In 2005, Novo Nordisk discontinued Actrapid
penﬁlls and recommended NovoRapid as an alternative
product. At the same time, they also withdrew Insulatard
Flexpen and Monotard from their range of human
insulin.
32 Since the withdrawal of Mixtard 30 at the end
of 2010, its 90000 users will have been changed to an
alternative product. It will be interesting to repeat this
study to assess whether these patients have been switched
to human insulin (the equivalent product is Humulin
M3) or indeed to analogue insulin. The Drug and Ther-
apeutics Bulletin has estimated that if all users of Mixtard
30 were switched to NovoMix 30, it would result in an
increase in cost of £9 million to the NHS in England
alone.
33
Table 3 Incremental cost of analogue insulin in the UK,
2000e2009
Year
Incremental cost
(£2010) (assuming
100% conversion
of analogue to
human insulin)
Incremental cost
(£2010) (assuming
50% conversion
of analogue to
human insulin)
2000 £5183001 £2591500
2001 £8065849 £4032924
2002 £10795155 £5397578
2003 £23143753 £11571877
2004 £39529331 £19764666
2005 £79448570 £39724285
2006 £98317347 £49158673
2007 £106139197 £53069598
2008 £121376170 £60688085
2009 £132895201 £66447601
Total £624893574 £312446787
Table 2 Average net ingredient cost (NIC) per millilitre in
the UK, 2000e2009
Year
NIC£2010/ml
for human insulin
NIC£2010/ml
for analogue insulin
2000 £1.60 £2.24
2001 £1.69 £2.24
2002 £1.76 £2.25
2003 £1.75 £2.33
2004 £1.74 £2.41
2005 £1.38 £2.36
2006 £1.37 £2.34
2007 £1.37 £2.27
2008 £1.35 £2.30
2009 £1.27 £2.25
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Incremental cost to the National Health Service of prescribing analogue insulinThe increase in the annual inﬂation-adjusted NHS
cost between 2000 and 2009 can be partly accounted for
by the increase in the prevalence of diabetes in the UK
during this time. In 1996, it was estimated that 1.4
million people in the UK had diabetes.
34 By 2004, this
ﬁgure had risen to 1.8 million
35 and to 2.6 million by
2009.
36 Patients with type 2 diabetes can be managed
with one or more of diet, oral glucose-lowering medica-
tion or insulin, whereas patients with type 1 diabetes are
dependent on exogenous insulin. However, the esti-
mated volume of analogue and human insulin dispensed
to patients with type 2 diabetes is far greater than for type
1 diabetes. This can be explained by the prevalence of
type 2 and type 1 diabetes in the UK. It has been esti-
mated that approximately 90% of people with diabetes in
the UK have type 2 diabetes. It can be further explained
by the nature of type 2 diabetes, which is characterised by
insulin resistance. Patients with type 2 diabetes are more
likely to be overweight or obese than patients with type 1
diabetes.
37 Therefore, those with type 2 diabetes using
insulin often receive higher insulin doses. Furthermore,
results from the United Kingdom Prospective Diabetes
Study (UKPDS) may have inﬂuenced the increased
prescribing of insulin to patients with type 2 diabetes so
that lower HbA1c levels could be obtained.
38
This study had inherent limitations. The calculation of
the incremental cost of analogue insulin was based on
the assumption that the same volume of insulin would be
prescribed if patients were switched from analogue to
human insulin. The PCA for Wales from 2000 to 2004
did not include the quantity of insulin dispensed which
was necessary to calculate the incremental cost. The
quantity, therefore, had to be calculated from the NIC
per quantity ﬁgures from the PCAs for England, Scot-
land and Northern Ireland. However, certain products in
the Welsh PCA were not available for the other regions
for the same year, so ﬁgures from the previous years had
to be used and adjusted for inﬂation. Some drugs were
listed only under their generic name in the Welsh PCA
and so a weighted-average NIC per quantity for the
branded products in the English PCA was used. The
same approach was taken when the drug name descrip-
tion did not specify whether the cartridge size was 1.5 ml
or 3 ml (when these were the only cartridge sizes on the
market). In addition, there were two drug names,
Human Actraphane and Human Protaphane phials,
which had no matches in any of the other PCAs for any
year. These are Novo Nordisk products, which tend to
carry the same cost per unit depending on whether they
are phial, penﬁll or preﬁlled pen and which is not
dependent on what type of human insulin is in the
device. Therefore, the NIC per quantity used for these
two products was the NIC per quantity of the other Novo
Nordisk phials. These assumptions were unlikely to have
impacted upon the estimates as a whole, since the NIC
and the volume of these products were small.
Another limitation was that the PCA only tells us how
much of each type of insulin was dispensed; thus, there
was no way of determining how much insulin was
dispensed to patients with type 2 diabetes speciﬁcally.
However, it is likely that the level of type 1 diabetes
remained relatively constant over the study period, while
the number of patients with type 2 diabetes is known to
have increased considerably.
39
The assumption that all patients using insulin
analogues could be equally well treated with human
insulin is also likely to be unrealistic. Dr Adler, chair of
the NICE guidance committee, has suggested that 90%
of patients with type 2 diabetes could receive human
insulin instead of long-acting insulin analogues, with
around two-thirds of these patients remaining on human
insulin.
14 Currently, however, there is no deﬁnitive ﬁgure
for how many people with diabetes could have received
human insulin instead of analogue insulin. The purpose
of this study was to calculate a monetary value to raise
awareness of the cost implications at a population level
of prescribing analogue insulin instead of human insulin
rather than to suggest an exact percentage of patients
Table 4 Estimated change in net ingredient cost (NIC) and volume of human and analogue insulin prescribed to patients with
type 1 and type 2 diabetes in the UK, 2000e2009
Year
NIC£2010 for
type 1 diabetes
NIC£2010 for
type 2 diabetes
Volume (ml) for type
1 diabetes
Volume (ml) for type
2 diabetes
Total
analogue
Total
human
Total
analogue
Total
human
Total
analogue
Total
human
Total
analogue
Total
human
2000 £11228382 £51444334 £6923103 £79075954 5038092 33056509 3050474 48350233
2001 £17858968 £55211316 £14564748 £92155033 8001813 33577135 6443335 53816755
2002 £25764159 £57242261 £24410582 £98670067 11520222 33039547 10827941 55441680
2003 £45316250 £49420126 £47585514 £94338575 19667109 28663444 20145487 53383153
2004 £65066374 £40577834 £76937127 £87354455 27296077 23712414 31672369 49905829
2005 £82462748 £28231889 £109393916 £67039353 35341564 21196772 45841398 47609677
2006 £97342547 £21284207 £140625903 £55238238 42215106 15771316 59651444 40046916
2007 £105277447 £17662770 £160494779 £49900346 46896096 13048606 70028562 36438609
2008 £113178916 £14924884 £179215091 £45134839 49542256 11113432 77455050 33486730
2009 £114597696 £12375736 £190322726 £38711902 51543528 9734567 84098018 30547933
Total £678093486 £348375355 £950473489 £707618762 297061863 222913742 409214078 449027514
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human instead of analogue insulin.
At the macroeconomic level, we know that the rise of
insulin analogues has had a substantial ﬁnancial impact
on the NHS, yet over the same period there has been no
observable clinical beneﬁt to justify that investment. It is
likely that there was and is considerable scope for
ﬁnancial savings. Most worryingly, the clinical role and
safety of insulin for use in people with type 2 diabetes is
being questioned.
40e43
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